drugset / Trial / NCT06313086
DP303c Versus Trastuzumab Emtansine in in Patients With HER2-positive Advanced Breast Cancer
RandomizedParallel-groupOpen-labelTreatment
Summary
A Clinical Study to Evaluate the Efficacy and Safety of DP303c versus trastuzumab emtansine in patients with HER2-positive Advanced Breast Cancer
Timeline
- Start
- 2024-03-13
- Primary completion
- 2025-12
- Completion
- 2028-02
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | TRASTUZUMAB ENVEDOTIN | Monoclonal antibody | 3 mg/kg | Intravenous |
| Comparator | Trastuzumab emtansine | Other / unclassified | 3.6 mg/kg | Intravenous |